349 related articles for article (PubMed ID: 27999408)
1. Cyclodextrins as Emerging Therapeutic Tools in the Treatment of Cholesterol-Associated Vascular and Neurodegenerative Diseases.
Coisne C; Tilloy S; Monflier E; Wils D; Fenart L; Gosselet F
Molecules; 2016 Dec; 21(12):. PubMed ID: 27999408
[TBL] [Abstract][Full Text] [Related]
2. Molecular Mind Games: The Medicinal Action of Cyclodextrins in Neurodegenerative Diseases.
Braga SS
Biomolecules; 2023 Apr; 13(4):. PubMed ID: 37189413
[TBL] [Abstract][Full Text] [Related]
3. Cyclodextrins: Assessing the Impact of Cavity Size, Occupancy, and Substitutions on Cytotoxicity and Cholesterol Homeostasis.
Szente L; Singhal A; Domokos A; Song B
Molecules; 2018 May; 23(5):. PubMed ID: 29783784
[TBL] [Abstract][Full Text] [Related]
4. Treatment with KLEPTOSE® CRYSMEB reduces mouse atherogenesis by impacting on lipid profile and Th1 lymphocyte response.
Montecucco F; Lenglet S; Carbone F; Boero S; Pelli G; Burger F; Roth A; Bertolotto M; Nencioni A; Cea M; Dallegri F; Fraga-Silva RA; Fougère L; Elfakir C; Gassner AL; Rudaz S; Parissaux X; Wils D; Salomé M; Vuilleumier N; Poggi A; Mach F
Vascul Pharmacol; 2015 Sep; 72():197-208. PubMed ID: 25921922
[TBL] [Abstract][Full Text] [Related]
5. Cyclodextrins, blood-brain barrier, and treatment of neurological diseases.
Vecsernyés M; Fenyvesi F; Bácskay I; Deli MA; Szente L; Fenyvesi É
Arch Med Res; 2014 Nov; 45(8):711-29. PubMed ID: 25482528
[TBL] [Abstract][Full Text] [Related]
6. Investigating the Mechanism of Cyclodextrins in the Treatment of Niemann-Pick Disease Type C Using Crosslinked 2-Hydroxypropyl-β-cyclodextrin.
Carradori D; Chen H; Werner B; Shah AS; Leonardi C; Usuelli M; Mezzenga R; Platt F; Leroux JC
Small; 2020 Nov; 16(46):e2004735. PubMed ID: 33079457
[TBL] [Abstract][Full Text] [Related]
7. Polyrotaxane-based systemic delivery of β-cyclodextrins for potentiating therapeutic efficacy in a mouse model of Niemann-Pick type C disease.
Tamura A; Yui N
J Control Release; 2018 Jan; 269():148-158. PubMed ID: 29138063
[TBL] [Abstract][Full Text] [Related]
8. Hydroxypropyl-beta and -gamma cyclodextrins rescue cholesterol accumulation in Niemann-Pick C1 mutant cell via lysosome-associated membrane protein 1.
Singhal A; Szente L; Hildreth JEK; Song B
Cell Death Dis; 2018 Oct; 9(10):1019. PubMed ID: 30282967
[TBL] [Abstract][Full Text] [Related]
9. Current insights on lipid nanocarrier-assisted drug delivery in the treatment of neurodegenerative diseases.
Teixeira MI; Lopes CM; Amaral MH; Costa PC
Eur J Pharm Biopharm; 2020 Apr; 149():192-217. PubMed ID: 31982574
[TBL] [Abstract][Full Text] [Related]
10. Cyclodextrins promote protein aggregation posing risks for therapeutic applications.
Wang MS; Boddapati S; Sierks MR
Biochem Biophys Res Commun; 2009 Aug; 386(3):526-31. PubMed ID: 19540204
[TBL] [Abstract][Full Text] [Related]
11. Intravenous 2-hydroxypropyl-β-cyclodextrin (Trappsol® Cyclo™) demonstrates biological activity and impacts cholesterol metabolism in the central nervous system and peripheral tissues in adult subjects with Niemann-Pick Disease Type C1: Results of a phase 1 trial.
Hastings C; Liu B; Hurst B; Cox GF; Hrynkow S
Mol Genet Metab; 2022 Dec; 137(4):309-319. PubMed ID: 36279795
[TBL] [Abstract][Full Text] [Related]
12. [Intracellularly Degradable Polyrotaxanes for Therapeutic Applications].
Tamura A
Yakugaku Zasshi; 2019; 139(2):143-155. PubMed ID: 30713223
[TBL] [Abstract][Full Text] [Related]
13. 2-Hydroxypropyl-β-cyclodextrins and the Blood-Brain Barrier: Considerations for Niemann-Pick Disease Type C1.
Calias P
Curr Pharm Des; 2017; 23(40):6231-6238. PubMed ID: 29065825
[TBL] [Abstract][Full Text] [Related]
14. Nasal biocompatible powder of Geraniol oil complexed with cyclodextrins for neurodegenerative diseases: physicochemical characterization and in vivo evidences of nose to brain delivery.
Truzzi E; Rustichelli C; de Oliveira Junior ER; Ferraro L; Maretti E; Graziani D; Botti G; Beggiato S; Iannuccelli V; Lima EM; Dalpiaz A; Leo E
J Control Release; 2021 Jul; 335():191-202. PubMed ID: 34019946
[TBL] [Abstract][Full Text] [Related]
15. Differential mode of cholesterol inclusion with 2-hydroxypropyl-cyclodextrins increases safety margin in treatment of Niemann-Pick disease type C.
Yamada Y; Ishitsuka Y; Kondo Y; Nakahara S; Nishiyama A; Takeo T; Nakagata N; Motoyama K; Higashi T; Arima H; Kamei S; Shuto T; Kai H; Hayashino Y; Sugita M; Kikuchi T; Hirata F; Miwa T; Takeda H; Orita Y; Seki T; Ohta T; Kurauchi Y; Katsuki H; Matsuo M; Higaki K; Ohno K; Matsumoto S; Era T; Irie T
Br J Pharmacol; 2021 Jul; 178(13):2727-2746. PubMed ID: 33782944
[TBL] [Abstract][Full Text] [Related]
16. Cyclodextrins in the treatment of a mouse model of Niemann-Pick C disease.
Camargo F; Erickson RP; Garver WS; Hossain GS; Carbone PN; Heidenreich RA; Blanchard J
Life Sci; 2001 Nov; 70(2):131-42. PubMed ID: 11787939
[TBL] [Abstract][Full Text] [Related]
17. Cyclodextrin-Based Macromolecular Systems as Cholesterol-Mopping Therapeutic Agents in Niemann-Pick Disease Type C.
Puglisi A; Yagci Y
Macromol Rapid Commun; 2019 Jan; 40(1):e1800557. PubMed ID: 30216584
[TBL] [Abstract][Full Text] [Related]
18. [Inclusion Solves Insolubility -Translational Research Cycle from Bedside to Bench and Bench to Bedside for Drug Development Targeting Niemann-Pick Disease Type C].
Irie T
Yakugaku Zasshi; 2022; 142(4):389-400. PubMed ID: 35370195
[TBL] [Abstract][Full Text] [Related]
19. Potential Use of the Cholesterol Transfer Inhibitor U18666A as a Potent Research Tool for the Study of Cholesterol Mechanisms in Neurodegenerative Disorders.
Yasamineh S; Mehrabani FJ; Derafsh E; Danihiel Cosimi R; Forood AMK; Soltani S; Hadi M; Gholizadeh O
Mol Neurobiol; 2024 Jun; 61(6):3503-3527. PubMed ID: 37995080
[TBL] [Abstract][Full Text] [Related]
20. Different solubilizing ability of cyclodextrin derivatives for cholesterol in Niemann-Pick disease type C treatment.
Yamada Y; Fukaura-Nishizawa M; Nishiyama A; Ishii A; Kawata T; Shirakawa A; Tanaka M; Kondo Y; Takeo T; Nakagata N; Miwa T; Takeda H; Orita Y; Motoyama K; Higashi T; Arima H; Seki T; Kurauchi Y; Katsuki H; Higaki K; Minami K; Yoshikawa N; Ikeda R; Matsuo M; Irie T; Ishitsuka Y
Clin Transl Med; 2023 Aug; 13(8):e1350. PubMed ID: 37620691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
